Heparin-induced anaphylactic and anaphylactoid reactions: Two distinct but overlapping syndromes

Expert Opinion on Drug Safety

Volumn 8, Issue 2, 2009, Pages 129-144

  Warkentin, Theodore E ^a   Greinacher, Andreas ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anaphylactic(oid) reactions; Bradykinin; Contact system; Contaminant; Hemodialysis; Heparin induced thrombocytopenia; Oversulfated chondroitin sulfate

Indexed keywords

AMINOPEPTIDASE; ANTITHROMBIN; ARDEPARIN; BRADYKININ; CARBOXYPEPTIDASE; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; CHONDROITIN SULFATE; DERMATAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE; DISACCHARIDE; ENOXAPARIN; FC RECEPTOR; FONDAPARINUX; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARAN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN; HYALURONIC ACID; IMMUNOGLOBULIN G ANTIBODY; KALLIKREIN; KERATAN SULFATE; LOW MOLECULAR WEIGHT HEPARIN; PENTOSAN POLYSULFATE; PENTOSANPOLYSULFAT SP54; PI 88; POLYANION; PREKALLIKREIN; THROMBOCYTE FACTOR 4; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTICOAGULANT AGENT;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTERY DISEASE; BLOOD SAMPLING; BRONCHOSPASM; CARDIOPULMONARY ARREST; CHEST TIGHTNESS; CHILL; CONTROLLED STUDY; CYSTITIS; DEPOLYMERIZATION; DIARRHEA; DISEASE ASSOCIATION; DRUG CONTAMINATION; DRUG EXPOSURE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSPNEA; EPIDEMIC; FEVER; FLUSHING; HEADACHE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNIZATION; INCIDENCE; LARYNX EDEMA; LEUKOCYTE ACTIVATION; LIMB AMPUTATION; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PHLEBOGRAPHY; REVIEW; RIGOR; RISK ASSESSMENT; SCINTIGRAPHY; SIDE EFFECT; STROKE; TACHYCARDIA; TACHYPNEA; THORAX PAIN; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; TRANSIENT GLOBAL AMNESIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VEIN THROMBOSIS; VOMITING; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPLEMENT ACTIVATION;

ANAPHYLAXIS; ANTICOAGULANTS; CHONDROITIN SULFATES; COMPLEMENT ACTIVATION; DRUG CONTAMINATION; HEPARIN; HUMANS; THROMBOCYTOPENIA;

EID: 66949114594     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902778180     Document Type: Review

References (100)

1. Chernoff AI. Anaphylactic reaction following injection of heparin. N Engl J Med 1950;242(9):315-319
2. Bernstein IL. Anaphylaxis to heparin sodium; report of a case, with immunologic studies. J Am Med Assoc 1956;161(14):1379-1381
3. Turcotte JG, Kraft RO, Fry WJ. Heparin reactions in patients with vascular disease. Arch Surg 1965;90:375-379
4. Nelson JC, Lerner RG, Goldstein R, Cagin NA. Heparin-induced thrombocytopenia. Arch Intern Med 1978;138(4):548-552 (Pubitemid 9032864)
5. Ansell JE, Clark WP Jr, Compton CC. Fatal reactions associated with intravenous heparin. Drug Intell Clin Pharm 1986;20(1):74-75 (Pubitemid 16175866)
6. Greinacher A, Michels I, Schäfer M, et al. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br J Haematol 1992;81(2):252-254 Report showing that Arteparon (type of OSCS formerly used to treat degenerative arthritis) can cause HIT, including associated anaphylactoid reactions.
7. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79(1):1-7 (Pubitemid 28037046)
8. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121(4):535-555 (Pubitemid 36645375)
9. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67(5):545-549
10. Greinacher A, Gopinadhan M, Günther JU, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006;26(10):2386- 2393 (Pubitemid 44465738)
11. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71(2):247-251 (Pubitemid 24047336)
12. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96(1):182-187 (Pubitemid 30456469)
13. Warkentin TE. Drug-induced immune-mediated thrombocytopenia - from purpura to thrombosis. N Engl J Med 2007;356(9):891-893 (Pubitemid 46339907)
14. Greinacher A, Warkentin TE. Heparin-induced thrombocytopenia. In: Aird WC, editor, Endothelial biomedicine. Cambridge: Cambridge University Press, 2007. p. 1344-1351 (ISBN 9780521853767)
15. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001;97(10):3300-3302
16. Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94(1):132-135
17. Platell CFE, Tan EGC. Hypersensitivity reactions to heparin: delayed onset thrombocytopenia and necrotizing skin lesions. Aust NZ J Surg 1986;56(8):621-623 • Authors note that patients who develop heparin-induced necrotizing skin lesions are at increased risk for HIT-associated anaphylactoid reactions. (Pubitemid 17205904)
18. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. Fourth edition. In: Warkentin TE, Greinacher A, editors, Heparin-induced thrombocytopenia. New York: Informa healthcare USA, Inc; 2007. p. 21-66
19. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest 2005;127(5):1857-1861 (Pubitemid 46218820)
20. Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia [abstract]. Blood 1992;80(Suppl 1):160a
21. Hewitt RL, Akers DL, Leissinger CA, et al. Concurrence of anaphylaxis and acute-heparin-induced thrombocytopenia in a patient with heparin-induced antibodies. J Vasc Surg 1998;28(3):561-565 • Evidence is presented that HIT-associated anaphylactoid reactions are associated with IgG rather than IgE anti-PF4/heparin antibodies. (Pubitemid 28421732)
22. Mims MP, Manian P, Rice L. Acute cardiovascular collapse from heparin: a consequence of heparin-induced thrombocytopenia. Eur J Haematol 2004;72(5):366-369 (Pubitemid 38520737)
23. Hartman V, Malbrain M, Daelemans R, et al. Pseudo-pulmonary embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis patients: safety of resuming heparin after disappearance of HIT antibodies. Nephron Clin Pract 2006;104(4):c143-8 (Pubitemid 44875770)
24. Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164(1):66-70 (Pubitemid 38067390)
25. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 2008;121(7):632-636 (Pubitemid 351876183)
26. Ling E, Warkentin TE. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiol 1998;89(6):1567-1569 (Pubitemid 29001598)
27. Heddle NM, Klama L, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med 1994;331(10):625-628 (Pubitemid 24276861)
28. Warkentin TE. Heparin-induced thrombocytopenia and the anesthesiologist. Can J Anesth 2002;49(6):S36-49 (Pubitemid 34928605)
29. Popov D, Zarrabi MH, Foda H, Graber M. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997;29(3):449-452 (Pubitemid 27106569)
30. Warkentin TE, Hirte HW, Anderson DR, et al. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 1994;97(5):489-491 (Pubitemid 24345602)
31. Shekhar R. Transient global amnesia - a review. Int J Clin Pract 2008;62(6):939-942 (Pubitemid 351691485)
32. Tholl U, Greinacher A, Overdick K, Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 1997;12(12):2750-2755 (Pubitemid 27520712)
33. Tejedor Alonso MA, López Revuelta K, García Bueno MJ, et al. Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient. Clin Nephrol 2005;63(3):236-240 (Pubitemid 40361266)
34. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108(17):2062-2065 (Pubitemid 37337579)
35. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99(5):819-829 (Pubitemid 351705298)
36. Bircher AJ, Czendlik CH, Messmer SL, et al. Acute urticaria caused by subcutaneous recombinant hirudin: evidence for an IgG-mediated hypersensitivity reaction. J Allergy Clin Immunol 1996;98(5 Pt 1):994-996 (Pubitemid 26405902)
37. Weiss ME, Nyhan D, Peng ZK, et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med 1989;320(14):886-890 (Pubitemid 19101592)
38. Proebstle TM, Gall H, Jugert FK, et al. Specific IgE and IgG serum antibodies to thiamine associated with anaphylactic reaction. J Allergy Clin Immunol 1995;95(5 Part 1):1059-1060
39. Kraft D, Hedin H, Richter W, et al. Immunoglobulin class and subclass distribution of dextran-reactive antibodies in human reactors and non reactors to clinical dextran. Allergy 1982;37(7):481-489 (Pubitemid 12030851)
40. Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. Fourth edition. In: Warkentin TE, Greinacher A, editors, Heparin-induced thrombocytopenia. New York: informa healthcare USA, Inc; 2007. p. 67-116
41. Warkentin TE, Sheppard JI, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006;108(9):2937-2941 (Pubitemid 44776929)
42. Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 2008;122(2):211-220
43. Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. Fourth edition. In: Warkentin TE, Greinacher A, editors, Heparin-Induced Thrombocytopenia. New York: Informa Healthcare USA, Inc; 2007. p. 167-186
44. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005;105(1):131-138 (Pubitemid 40053074)
45. Handin RI, Cohen HJ. Purification and binding properties of human platelet factor four. J Biol Chem 1976;251(14):4273-4282
46. Greinacher A, Alban S, Dummel V, et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995;74(3):886-892 Features of carbohydrate structure that favor PF4 interactions and resulting immunogenicity are degree of sulfation, chain length and branching.
47. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106(12):3791-3796 (Pubitemid 41739014)
48. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105(1):139-144 (Pubitemid 40053075)
49. Alban S, Franz G. Gas liquid chromatography-mass spectrometry analysis of anticoagulant active curdlan sulfates. Semin Thromb Hemost 1994;20(2):152-158 (Pubitemid 24263664)
50. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008;26(6):669-675 •• A landmark study that identified OSCS as the contaminant within UFH associated with an epidemic of heparin-induced anaphylaxis. (Pubitemid 351824692)
51. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358(23):2457-2467 •• Laboratory studies (including use of porcine model) supporting contact system activation by OSCS as the explanation for an epidemic of heparin-induced anaphylaxis. (Pubitemid 351793019)
52. Blossom DB, Kallen A, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008;359(25):2674-2684
53. Pinals RS. Pharmacologic treatment of osteoarthritis. Clin Ther 1992;14(3):336-346
54. Dettmer N, Nowack H, Raake W. Thrombozyten-aggregation nach heparin und Arteparon®. Klinishce Bedeutung thrombocyte aggregation following heparin and Arteparon. Clinical significance-article in German. MMW Munch Med Wochenschr 1983;125(25):540-542
55. Wolf H, Nowack H, Wick G. Detection of antibodies interacting with glycosaminoglycan polysulfate in patients treated with heparin or other polysulfated glycosaminoglycans. Int Arch Allergy Appl Immunol 1983;70(2):157-163 (Pubitemid 13171433)
56. Yu G, Gunay NS, Linhardt RJ, et al. Preparation and anticoagulant activity of the phosphosulfomannan PI-88. Eur J Med Chem 2002;37(10):783-791 (Pubitemid 35350842)
57. Rosenthal MA, Rischin D, McArthur G, et al. Treatment with the novel antiangiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann Oncol 2002;13(5):770-776 (Pubitemid 34567385)
58. Goad KE, Horne MK III, Gralnick HR. Pentosan-induced thrombocytopenia: support for an immune complex mechanism. Br J Haematol 1994;88(4):803-808 (Pubitemid 24375796)
59. Weimann G, Lubenow N, Selleng K, et al. Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia. Eur J Haematol 2001;66(3):195-199 (Pubitemid 32324586)
60. Centers for Disease Control and Prevention (CDC). Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 2008;57(5):124-125 Characterizes the epidemiologic features of heparin-induced anaphylaxis first recognized in the US in November 2007
61. Contaminant detected in heparin material of specified origin in the USA and in Germany; serious adverse events reported; recall measures initiated. World Health Organization Alert No.118 (7 March 2008). Available from: http://www.who.int/medicines/publications/drugalerts/Alert-118-Heparin.pdf
62. Notice of recall from Rotexmedica to Bfarm (German Regulatory Authorities). Rotexmedica/Bfarm Notice (7 March 2008). Available from: http://www:akdae.de/20/40/Archiv/ 2008/20080310.pdf
63. Heparin recall information. Baxter Investigation Updates (5,14,19 March 2008;). Available from: http://www.baxter.com/products/biopharmaceuticals/ heparin/html
64. Schwartz LB. Heparin comes clean. N Engl J Med 2008;358(23):2505-2509 (Pubitemid 351793026)
65. Maruyama T, Toida T, Imanari T, et al. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998;306(1-2):35-43 (Pubitemid 28304973)
66. Avorn J. Coagulation and adulteration-building on science and policy lessons from 1905. N Engl J Med 2008;358(23):2429-2431 • An editorial commentary that concludes OSCS contaminating heparin is an adulterant. (Pubitemid 351793016)
67. Zhang Z, Weïwer M, Li B, et al. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 2008;51(18):5498-5501
68. Hojima Y, Cochrane CG, Wiggins RC, et al. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984;63(6):1453-1459
69. Perseghin P, Capra M, Baldini V, Sciorelli G. Bradykinin production during donor plasmapheresis procedures. Vox Sang 2001;81(1):24-28 (Pubitemid 35334299)
70. 9-bradykinin after contact activation. Transfusion 2002;42(11):1458-1465
71. Cyr M, Eastlund T, Blais C Jr, et al. Bradykinin metabolism and hypotensive transfusion reactions. Transfusion 2001;41(1):136-150 (Pubitemid 32143749)
72. Hild M, Söderström T, Egberg N, Lundahl J. Kinetics of bradykinin levels during and after leucocyte filtration of platelet concentrates. Vox Sang 1998;75(1):18-25 (Pubitemid 28432797)
73. Takahashi TA, Abe H, Hosada M, et al. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter. Transfusion 1995;35(11):967 (Pubitemid 26141051)
74. Arnold DM, Molinaro G, Warkentin TE, et al. Hypotensive transfusion reactions can occur with blood products that are leukoreduced before storage. Transfusion 2004;44(9):1361-1366 • Identifies constitutive and acquired risk factors for transfusion-associated anaphylactoid reactions. (Pubitemid 39129251)
75. Blais C Jr, Marc-Aurele J, Simmons WH, et al. Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. Peptides 1999;20(4):421-430 (Pubitemid 29458983)
76. Lasser EC. Sulfated surfaces in hypersensitivity: an 'on-off ' switch for anaphylaxis? Med Hypotheses 1991;34(1):13-19
77. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006;61(2):211-220 (Pubitemid 43381833)
78. Tielemans C, Madhoun P, Lenaers M, et al. Anaphylactoid reactions during hemodialysis during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990;38(5):982-984 (Pubitemid 20362873)
79. Verresen L, Water M, Vanrenterghem Y, Michielsen P. Angiotensin- converting-enzyme inhibitors and anaphylatoid reactions to high-flux membrane dialysis. Lancet 1990;336(8727):1360-1362
80. John B, Anijeet HK, Ahmad R. Anaphylactic reaction during haemodialysis on AN69 membrane in a patient receiving angiotensive II receptor antagonist. Nephrol Dial Transplant 2001;16(9):1955-1956 (Pubitemid 32821442)
81. Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994;45(5):1497-1503 (Pubitemid 24135039)
82. Coppo R, Amore A, Cirina P, et al. Bradykinin and nitric oxide generation by dialysis membranes can be blunted by alkaline rinsing solutions. Kidney Int 2000;58(2):881-888 (Pubitemid 30620039)
83. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine9-bradykinin. J Pharmacol Exp Ther 2002;303(1):232-237 (Pubitemid 35056473)
84. Daugirdas JT, Ing TS, Roxe DM, et al. Severe anaphylactoid reactions to cuprammonium cellulose hemodialyzers. Arch Intern Med 1985;145(3):489-494 (Pubitemid 15140745)
85. Rumpf KW, Seubert S, Seubert A, et al. Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients. Lancet 1985;2(8469-70):1385-1387 (Pubitemid 16138552)
86. Lemke HD, Heidland A, Schaefer RM. Hypersensitivity reactions during haemodialysis: role of complement fractions and ethylene oxide antibodies. Nephrol Dial Transplant 1990;5(4):264-269 (Pubitemid 20204468)
87. Maurice F, Rivory JP, Larsson PH, et al. Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis. J Allergy Clin Immunol 1986;77(4):594-597 (Pubitemid 16101448)
88. Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37(4):743-749 (Pubitemid 32268035)
89. Ueda A, Nagase S, Morito N, et al. Anaphylactoid reaction induced by low-molecular-weight heparin in a hemodialysis patient. Nephron 2001;87(1):93-94 (Pubitemid 32171127)
90. Berkun Y, Haviv YS, Schwartz LB, Shalit M. Heparin-induced recurrent anaphylaxis. Clin Exp Allergy 2004;34(12):1916-1918 (Pubitemid 40023644)
91. Harenberg J, Hoffmann U, Huhle G, et al. Cutaneous reactions to anticoagulants. Recognition and management. Am J Clin Dermatol 2001;2(2):69-75 (Pubitemid 32592523)
92. Ebo DG, Haine SE, Hagendorens MM, et al. Hypersensitivity to nadroparin calcium. Clin Drug Invest 2004;24(7):421-426
93. Sato K, Kazama JJ, Wada Y, et al. Hypersensitivity to paraoxybenzoic acid esters (parabens) in a dialysis patient. Nephron 2002;92(3):728-729 (Pubitemid 35316881)
94. Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008;359(12):1291-1292 Provides epidemiologic evidence suggesting that OSCS-contaminated heparin could have a higher risk of inducing HIT compared with non-contaminated heparin.
95. Casu B, Johnson EA, Mantovani M, et al. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparin sulphates. Arzneimittelforschung 1983;33(1):135-142 (Pubitemid 13222125)
96. Francis JL, Palmer GJ III, Moroose R, Drexler A. Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery. Ann Thorac Surg 2003;75(1):17-22 (Pubitemid 36099015)
97. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. Eighth edition. American college of chest physicians evidence-based clinical practice guidelines. Chest 2008;133(Suppl):340S-80S
98. Warkentin TE, Sheppard JI, Moore JC, et al. Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;6(8):1304-1312 (Pubitemid 352016309)
99. FDA seizes contaminated heparin from a Cincinnati manufacturer. FDA News (6 November 2008). Available from: http://www.fda.gov/bbs/topics/NEWS/2008/ NEW01912
100. Wang L, Buchanan S, Meyerhoff ME. Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem 2008[Epub ahead of print]